Anti-infective Drugs Market - Size, Share, Outlook,
and Opportunity Analysis, 2018 – 2026
Infectious diseases are health disorders that are caused by invasion and multiplication of
infection-causing foreign organisms in a host’s body. Growth and multiplication of harmful
pathogens such as bacteria, viruses, fungi, and parasites causes major infections in the host
body. Infection can be transmitted through skin contact, bodily fluids, airborne particles, or
touching an infected object. Anti-infective drugs are used for the treatment of infectious diseases
or conditions. Anti-infective drugs act by inhibiting the growth or by eliminating the infectious
agents.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2489
Anti-infective Drugs Market: Drivers
Key players in the market are focused on new product launch, which is expected to boost the
anti-infective drugs market growth. For instance, in January 2018, Melinta Therapeutics, Inc.
launched its intravenous and oral formulations of Baxdela (delafloxacin) in the U.S. Baxdela is
intended for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused
by designated susceptible bacteria including gram positive bacteria and gram negative bacteria.
Moreover, increasing prevalence of sepsis is expected to boost growth of the anti-infective drug
market. Sepsis is a life-threatening condition caused by the body’s response to an infection. For
instance, according to the World Health Organization’s (WHO) report, 2018, over 30 million
people worldwide are affected with sepsis that leads to 6 million deaths, annually. Moreover,
over three million newborns and 1.2 million children suffer from sepsis worldwide, annually.
Furthermore, increasing number of pipeline studies to develop anti-infective drugs for the
treatment of rare infectious diseases is contributing to growth of the anti-infective drugs market.
For instance, in January 2019, National Institute of Allergy and Infectious Diseases (NIAID)
initiated phase 2/phase 3 clinical trial to study the safety and effectiveness of four drugs